Compare Stocks → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:ICO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICOiCo TherapeuticsC$0.11C$0.11C$0.02▼C$0.16C$952KN/A3.16 million shs1.31 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICOiCo Therapeutics0.00%0.00%0.00%0.00%0.00%Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICOiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICOiCo TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICOiCo TherapeuticsN/AN/AC$0.01 per share8.75C$0.00 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICOiCo TherapeuticsN/A-C$0.01N/A∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICOiCo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICOiCo TherapeuticsN/A1.141.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICOiCo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipICOiCo TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableICOiCo TherapeuticsN/A9.07 millionN/ANot OptionableICO, MTPH, LCT, and MEB HeadlinesRecent News About These CompaniesMay 28, 2024 | msn.comLego Zelda Great Deku Tree set interview – ‘This is a very important model to all of us’May 27, 2024 | metro.co.ukX Factor’s Levi Davis’ family hopes new documentary on missing star will lead to breakthrough in cold caseMay 22, 2024 | metro.co.ukRylan Clark says he ‘can’t sing’ anymore after behind-the-scenes The X Factor traumaMay 22, 2024 | metro.co.ukRylan Clark says he was ‘thrown into the lion’s den’ on The X FactorMay 19, 2024 | investing.comLirum Therapeutics Inc (LRTX)May 16, 2024 | msn.comRylan Clark’s secret music success with fake name 12 years after X FactorMay 15, 2024 | msn.comX Factor legend ‘counting her lucky stars family is safe’ after car accident with childrenMay 14, 2024 | msn.comZelda player upset that he didn’t lose 250 hours of save data during 100% runMay 13, 2024 | msn.comNew Switch 2 rumours hint at Breath Of The Wild remake and playable ZeldaMay 12, 2024 | msn.comX Factor winner slams ‘dangerous’ reality TV and gives stark warningMay 11, 2024 | msn.comCara Delevingne begins demolition on $7,000,000 Los Angeles mansion after devastating fireMay 8, 2024 | msn.comX Factor legend to star in musical about Gwyneth Paltrow’s ski crashMay 8, 2024 | msn.comCara Delevingne forced to deny being ‘coked up’ after awkward red carpet interviewMay 6, 2024 | metro.co.ukThe moment ‘completely broken’ Dannii Minogue wanted to ‘run’ from The X FactorMay 3, 2024 | msn.comX Factor star ‘attacked and mugged’ in unsettling incidentMay 1, 2024 | msn.comX Factor legend hasn’t aged a day 19 years after controversial exitMay 1, 2024 | msn.comCancer jab marks huge breakthrough in battle against deadly brain tumoursMay 1, 2024 | msn.comZelda director wants to make ‘grounded’ movie with less motion captureApril 30, 2024 | metro.co.ukX Factor legend responds to ‘satanic panic’ over drastic new lookApril 30, 2024 | metro.co.ukX Factor legend has best response after bizarre ‘satanic’ criticism over her transformationMedia Sentiment Over TimeTop Headlines3 Value Stocks You Can Buy Before They Become BigMay 6, 2024 8:00 AMView 3 Value Stocks You Can Buy Before They Become Big3 Stocks Nancy Pelosi Has Been BuyingMay 10, 2024 8:35 AMView 3 Stocks Nancy Pelosi Has Been BuyingMU Nears Breakout as Analysts Continue to Pound the TableMay 8, 2024 7:11 AMView MU Nears Breakout as Analysts Continue to Pound the TableAnalysts Still Want Double-Digit Upside Out of Applied MaterialsMay 17, 2024 9:12 AMView Analysts Still Want Double-Digit Upside Out of Applied MaterialsAnalog Devices Extends Rally: Signals Start to Cyclical RecoveryMay 23, 2024 6:15 AMView Analog Devices Extends Rally: Signals Start to Cyclical RecoveryAll HeadlinesCompany DescriptionsiCo TherapeuticsCVE:ICOiCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
